| Outcome Measures: |
Primary: Postprandial increase in intact Proinsulin levels (Peak, AUC), 30, 60, 90, 120, 150, 180, 210, 240, 270 300 mins post test meal procedure, 3 times within 12 weeks treatment|Postprandial Proinsulin/Insulin Ratio, after 12 weeks treatment|Fasting intact Proinsulin levels, after 12 weeks treatment|Fasting Proinsulin/Insulin Ratio, after 12 weeks treatment|Fasting Blood Glucose, after 12 weeks treatment|Postprandial Blood Glucose Excursions (Peak; AUC), 30, 60, 90, 120, 150, 180, 210, 240, 270 300 mins post test meal procedure, 3 times within 12 weeks treatment|Fasting Lipids, after 12 weeks treatment|Postprandial Lipids, after 12 weeks treatment|Fasting Erythrocyte Flexibility, after 12 weeks treatment|Postprandial Erythrocyte Flexibility, after 12 weeks treatment|Fasting GLP-1 levels, after 12 weeks treatment|Postprandial GLP-1 levels, after 12 weeks treatment|Fasting cGMP, after 12 weeks treatment|Postprandial cGMP, after 12 weeks treatment|Fasting Calcitonin, after 12 weeks treatment|Fasting PAI-1 levels, after 12 weeks treatment|Postprandial PAI-1 levels, after 12 weeks treatment|Fasting ADMA levels, after 12 weeks treatment|Postprandial ADMA levels, after 12 weeks treatment|Fasting Malonyldialdehyd, after 12 weeks treatment|fasting oxidatively modified nucleosides 8-oxodG and 8-oxoGuo, after 12 weeks treatment | Secondary: Hypoglycemic events, after 12 weeks treatment|Body Weight, after 12 weeks treatment
|
